QureTech Bio AB logo

QureTech Bio AB

QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. The global market for antibiotics is estimated at USD 38 billion with USA, Europe and Japan representing 50%. The cost of antibiotic resistance to medical communities in the EU alone is conservatively estimated to be €1.5 billion and the availability of new targeted antibiotics of this type would generate significant cost savings for healthcare systems.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://quretech.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Box 7995SE-907 36
Umeï
Sweden
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/quretech-bio-ab” connections=”true” suffix=””]